Larry Zhang - 24 Jul 2021 Form 4 Insider Report for CASI Pharmaceuticals, Inc.

Role
President
Signature
/s/ Cynthia W. Hu, COO (US), Gen Counsel and Secretary
Issuer symbol
N/A
Transactions as of
24 Jul 2021
Net transactions value
$0
Form type
4
Filing time
26 Jul 2021, 18:08:05 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CASI Employee Stock Option (Right to Buy) Award $0 -800,000 -50% $0.000000 800,000 24 Jul 2021 Common Stock 800,000 $1.28 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option grant was approved by the Compensation Committee on July 24, 2021. The exercise price per share is the closing market price on July 23, 2021, the last trading day preceding the date of grant.
F2 The stock options will vest as follows: 25 percent on each of the first, second, third and fourth anniversaries of the date of grant.